关键词: font-size:medium, ">紫杉醇；合理用药；预处理；临床药师

Abstract: Objective： The use of paclitaxel in tumor chemotherapy patients in our hospital was statistically analyzed by clinical pharmacists to provide reference for rational drug use of paclitaxel. Methods： Through“decision support system for clinical safe and rational drug use”， the clinical data of patients received formulations of paclitaxel from July to December in 2019 was collected， and the rationality of the clinical application of paclitaxel formulations were evaluated according to the drug instructions， Guidelines of Chinese Society of Clinical Oncology (CSCO) for the Diagnosis and Treatment of Esophageal Cancer（2019 edition）， and Guidelines of Chinese Society of Clinical Oncology (CSCO) for Breast Cancer Diagnosis and Treatment(2019 edition)， etc. Results： A total of 95 patients received chemotherapy with paclitaxel formulations， of which 58 had unreasonable drug use， and the rational rate of drug use was 38.95%. The main types of unreasonable drug use were the impropriety dosage of paclitaxel formulations and improper drug pretreatment. The improper drug pretreatment included inappropriate usage and dosage， inappropriate timing of administration， inappropriate course of treatment. Conclusion： The retionality rate of the use of paclitaxel formulations in our hospital is low. On the one hand， the dosage of paclitaxel (albumin bound) should be standardized to ensure the treatment effect of patients. On the other hand， physicians should pay attention to the drug pretreatment of paclitaxel， and standardize the timing， dosage and course of the use of the pretreatment drugs in order to ensure safe medication for patients.

Key words: font-size:medium, ">Paclitaxel； Rational drug use； Pretreatment； Clinical pharmacists